These EGFR targeted nanoparticles exploit the overexpression of growth factor receptors in hypoxic  multidrug resistant cancer and inhibit the Warburg Effect by delivering Lonidamine (a hexokinase 2 inhibitor) Lonidamine lowers the apoptotic threshold for paclitaxel and the drug combination reverses multidrug resistance in triple negative breast cancer